Predicting and Defining Vancomycin Efficacy: Program Overview

Clinical Infectious Diseases, Jan 2006

Robert C. Moellering Jr., Patrice Courvalin, Ronald N. Jones, Donald P. Levine, Michael J. Rybak, Dennis L. Stevens, George Sakoulas

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://cid.oxfordjournals.org/content/42/Supplement_1/S1.full.pdf

Predicting and Defining Vancomycin Efficacy: Program Overview

CME ARTICLE • CID Course Faculty Disclosures 0 1 0 Disclosure policy. It is the policy of Boston University School of Medicine, Department of Continuing Medical Education, that faculty disclose to program participants any real or ap- parent conflict of interest. In addition, faculty are asked to disclose when any unapproved use of pharmaceuticals and de- vices is being discussed. Authors. Robert C. Moellering , Jr., MD (Chairman , De- partment of Medicine, Beth Israel Deaconess Medical Center , Boston, MA), is a consultant to Aventis, Cubist, Pfizer , and Vicuron and serves on the speakers' bureaus of Aventis, Cubist, and Pfizer. Dr. Moellering does not discuss unlabeled/investi- gational uses of a commercial product. Patrice Courvalin, MD (Professor and Head, Antibacterial Agents Unit, National Reference Center for Antibiotics, Institut 1 Robert C. Moellering, Jr., Patrice Courvalin, Ronald N. Jones , Donald P. Levine, Michael J. Rybak, Dennis L. Stevens, and George Sakoulas Release and Expiration Dates Release date: 1 January 2006. Expiration date: 1 January 2009. - CME INFORMATION AND INSTRUCTIONS Accreditation Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. Boston University School of Medicine designates this educational activity for a maximum of 3 category 1 credits toward the American Medical Association Physician’s Recognition Award. Physicians should claim only those credits that they actually spent in the activity. To successfully complete this activity, participants are required to read the entire supplement and complete and submit the test answer sheet by 1 May 2008. CME credit will be awarded if a score of 70% or better is achieved. A certificate of credit will be sent within 6 weeks of receipt of the test answers to those participants who successfully complete the test. The estimated time to review the supplement and complete the accompanying test is 3 hours. Target Audience This educational activity is intended for infectious diseases specialists. Educational Needs Participants will gain insight into the treatment of patients with infections caused by strains of methicillin-resistant Staphylococcus aureus (MRSA). For many years, vancomycin has been the standard of care for treating infections caused by MRSA pathogens. However, since the 1990s, resistance to vancomycin has emerged among MRSA strains; thus, understanding the optimal clinical application of vancomycin is of great importance. Educational Objectives At the conclusion of this activity, participants will be able to 1. discuss the pharmacokinetics and pharmacodynamics of vancomycin and the clinical implications of its use, 2. describe the potential molecular mechanisms of bacterial resistance to antibiotic agents, and 3. illustrate the methodologies used to test resistance and susceptibility to vancomycin in bacteria, as well as the drawbacks and the clinical implications thereof. Grant Support This educational activity is supported by an unrestricted grant from Cubist Pharmaceuticals. Disclaimer This CME program is intended solely for educational purposes for qualified health care professionals. In no event shall Boston University be liable for any decision made or action taken in reliance on the information contained in the program. In no event should the information contained in the program be used as a substitute for professional care. No physician-patient relationship is being established. Pasteur, Paris, France), is a consultant to Sanofi-Synthelabo and Grunenthal. Dr. Courvalin does not discuss unlabeled/ investigational uses of a commercial product. Ronald N. Jones, MD (Professor [Adjunct] of Medicine, Tufts University School of Medicine, Boston, MA), is President and CEO of JMI Laboratories (The JONES Group). He has received grant and/or research support from AB BIODISK, Abbott, Arpida, AstraZeneca, Basilea, Bayer, BD Microbiology Systems, Boehringer-Ingelheim, Bristol-Myers Squibb, Centers for Disease Control and Prevention, Cognigen, Cubist, Daiichi, Elan (Dura), Elanco, Gensoft, GlaxoSmithKline, Intrabiotics, LG Health Sciences, Micrologix Biotech, MicroScan, Novartis, Peninsula, Pfizer, Pharmacia, Schering-Plough, Sequoia, TREK, Unimed, Vicuron (Versicor), and Wyeth. Dr. Jones does not discuss unlabeled/investigational uses of a commercial product. Donald P. Levine, MD (Chief, Division of General Internal Medicine, Wayne State University, Detroit, MI), has received grant and/or research support from Cubist, Nabi, and Wyeth and is a consultant to Cubist. Dr. Levine does not discuss unlabeled/investigational uses of a commercial product. Michael J. Rybak, PharmD (Associate Dean for Research, Professor of Pharmacy and Medicine, Director, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI), has received (...truncated)


This is a preview of a remote PDF: https://cid.oxfordjournals.org/content/42/Supplement_1/S1.full.pdf

Robert C. Moellering Jr., Patrice Courvalin, Ronald N. Jones, Donald P. Levine, Michael J. Rybak, Dennis L. Stevens, George Sakoulas. Predicting and Defining Vancomycin Efficacy: Program Overview, Clinical Infectious Diseases, 2006, pp. S1-S2, 42/Supplement 1, DOI: 10.1086/491715